Literature DB >> 8988170

Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel.

O Zhuchenko1, J Bailey, P Bonnen, T Ashizawa, D W Stockton, C Amos, W B Dobyns, S H Subramony, H Y Zoghbi, C C Lee.   

Abstract

A polymorphic CAG repeat was identified in the human alpha 1A voltage-dependent calcium channel subunit. To test the hypothesis that expansion of this CAG repeat could be the cause of an inherited progressive ataxia, we genotyped a large number of unrelated controls and ataxia patients. Eight unrelated patients with late onset ataxia had alleles with larger repeat numbers (21-27) compared to the number of repeats (4-16) in 475 non-ataxia individuals. Analysis of the repeat length in families of the affected individuals revealed that the expansion segregated with the phenotype in every patient. We identified six isoforms of the human alpha 1A calcium channel subunit. The CAG repeat is within the open reading frame and is predicted to encode glutamine in three of the isoforms. We conclude that a small polyglutamine expansion in the human alpha 1A calcium channel is most likely the cause of a newly classified autosomal dominant spinocerebellar ataxia, SCA6.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8988170     DOI: 10.1038/ng0197-62

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  338 in total

1.  Patterns of instability of expanded CAG repeats at the ERDA1 locus in general populations.

Authors:  R Deka; S Guangyun; J Wiest; D Smelser; S Chunhua; Y Zhong; R Chakraborty
Journal:  Am J Hum Genet       Date:  1999-07       Impact factor: 11.025

Review 2.  The localization and interactions of huntingtin.

Authors:  A L Jones
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

3.  Autosomal dominant cerebellar ataxia type III: linkage in a large British family to a 7.6-cM region on chromosome 15q14-21.3.

Authors:  P F Worth; P Giunti; C Gardner-Thorpe; P H Dixon; M B Davis; N W Wood
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

4.  Increased T-type Ca2+ channel activity as a determinant of cellular toxicity in neuronal cell lines expressing polyglutamine-expanded human androgen receptors.

Authors:  A Sculptoreanu; H Abramovici; A A Abdullah; A Bibikova; V Panet-Raymond; D Frankel; H M Schipper; L Pinsky; M A Trifiro
Journal:  Mol Cell Biochem       Date:  2000-01       Impact factor: 3.396

5.  Ablation of P/Q-type Ca(2+) channel currents, altered synaptic transmission, and progressive ataxia in mice lacking the alpha(1A)-subunit.

Authors:  K Jun; E S Piedras-Rentería; S M Smith; D B Wheeler; S B Lee; T G Lee; H Chin; M E Adams; R H Scheller; R W Tsien; H S Shin
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

Review 6.  Ion channel genes and human neurological disease: recent progress, prospects, and challenges.

Authors:  E C Cooper; L Y Jan
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

Review 7.  Molecular determinants of inactivation in voltage-gated Ca2+ channels.

Authors:  S Hering; S Berjukow; S Sokolov; R Marksteiner; R G Weiss; R Kraus; E N Timin
Journal:  J Physiol       Date:  2000-10-15       Impact factor: 5.182

8.  Ion channels in health and disease. 83rd Boehringer Ingelheim Fonds International Titisee Conference.

Authors:  B A Niemeyer; L Mery; C Zawar; A Suckow; F Monje; L A Pardo; W Stuhmer; V Flockerzi; M Hoth
Journal:  EMBO Rep       Date:  2001-07       Impact factor: 8.807

9.  Modulation of slow inactivation in class A Ca2+ channels by beta-subunits.

Authors:  S Sokolov; R G Weiss; E N Timin; S Hering
Journal:  J Physiol       Date:  2000-09-15       Impact factor: 5.182

Review 10.  Unraveling monogenic channelopathies and their implications for complex polygenic disease.

Authors:  J Jay Gargus
Journal:  Am J Hum Genet       Date:  2003-03-07       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.